Component

Scyllo-inositol

Scyllo-inositol. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The 250-mg twice-daily scyllo-inositol group had reduced CSF amyloid-beta x-42 despite no significant clinical benefit.

    Scyllo-inositol → CSF amyloid-beta x-42 concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"}
    experimental_model
    Randomized dose-ranging phase 2 trial
    exposure
    Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks
    limitations
    Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.
    nutrient_topic
    Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
    organism
    Homo sapiens
    plain_language
    A biomarker moved without demonstrated improvement in how patients functioned.
    primary_references
    [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    tissue_or_cell_type
    353 participants with mild-to-moderate Alzheimer disease

    Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1484–1495

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized dose-ranging phase 2 trial · source_derived_draft · unverified_draft

    ### ino-scyllo-biomarker The 250-mg twice-daily scyllo-inositol group had reduced CSF amyloid-beta x-42 despite no significant clinical benefit. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: A biomarker moved without demonstrated improvement in how patients functioned. organism: Homo sapiens tissue_or_cell_type: 353 participants with mild-to-moderate Alzheimer disease experimental_model: Randomized dose-ranging phase 2 trial limitations: Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit. exposure: Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks evidence_span: {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"} [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    Complete structured claim and evidence

  2. The main 250-mg scyllo-inositol versus placebo analysis found no significant benefit on cognition or daily-function coprimary outcomes.

    Scyllo-inositol → Cognition and daily function in Alzheimer disease trials source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"}
    experimental_model
    Randomized dose-ranging phase 2 trial
    exposure
    Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks
    limitations
    Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.
    nutrient_topic
    Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
    organism
    Homo sapiens
    plain_language
    Changing the inositol form does not guarantee a neurological benefit.
    primary_references
    [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    tissue_or_cell_type
    353 participants with mild-to-moderate Alzheimer disease

    Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1471–1482

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized dose-ranging phase 2 trial · source_derived_draft · unverified_draft

    ### ino-scyllo-clinical The main 250-mg scyllo-inositol versus placebo analysis found no significant benefit on cognition or daily-function coprimary outcomes. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: Changing the inositol form does not guarantee a neurological benefit. organism: Homo sapiens tissue_or_cell_type: 353 participants with mild-to-moderate Alzheimer disease experimental_model: Randomized dose-ranging phase 2 trial limitations: Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit. exposure: Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks evidence_span: {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"} [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    Complete structured claim and evidence

  3. The 1000- and 2000-mg twice-daily scyllo-inositol groups were stopped early after an imbalance of infections and deaths.

    Scyllo-inositol → Trial infection and death imbalance source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"}
    experimental_model
    Randomized dose-ranging phase 2 trial
    exposure
    Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks
    limitations
    Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.
    nutrient_topic
    Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
    organism
    Homo sapiens
    plain_language
    Higher-dose safety findings belong to this stereoisomer and regimen, and should remain visible.
    primary_references
    [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    tissue_or_cell_type
    353 participants with mild-to-moderate Alzheimer disease

    Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1497–1508

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized dose-ranging phase 2 trial · source_derived_draft · unverified_draft

    ### ino-scyllo-safety The 1000- and 2000-mg twice-daily scyllo-inositol groups were stopped early after an imbalance of infections and deaths. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: Higher-dose safety findings belong to this stereoisomer and regimen, and should remain visible. organism: Homo sapiens tissue_or_cell_type: 353 participants with mild-to-moderate Alzheimer disease experimental_model: Randomized dose-ranging phase 2 trial limitations: Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit. exposure: Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks evidence_span: {"source_cache": "artifacts/inositol-research/21917766.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040", "start_char": 0, "end_char": 1479, "text_sha256": "12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040"} [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards